Diagnostic applications of nuclear medicine: Lymphomas

Heather A. Jacene; Sree Harsha Tirumani; Richard L. Wahl

doi:10.1007/978-3-319-26236-9_7

Diagnostic applications of nuclear medicine: Lymphomas

Heather A. Jacene, Sree Harsha Tirumani, Richard L. Wahl

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Hodgkin and non-Hodgkin lymphomas are lymphoid neoplasms arising from B cells, T cells, or NK (natural killer) cells. [¹⁸F]FDG PET/CT is more accurate for the primary staging of lymphoma, particularly because it can detect disease in normal-sized lymph nodes, liver, spleen, and bone marrow. A major advantage of [¹⁸F]FDG PET in determining the outcome of therapy is distinguishing active lymphoma from fibrosis/ necrosis in residual masses. Posttherapy [¹⁸F] FDG PET provides important prognostic information and has been incorporated into the currently used criteria for evaluating response to therapy in lymphoma (Lugano/Lyric Classifications). Interim [¹⁸F]FDG PET/CT also provides prognostic information and is being evaluated for "risk-adapted therapy" in setting of clinical trials.

Original language	English
Title of host publication	Nuclear Oncology
Subtitle of host publication	From Pathophysiology to Clinical Applications
Publisher	Springer International Publishing
Pages	353-393
Number of pages	41
ISBN (Electronic)	9783319262369
ISBN (Print)	9783319262345
DOIs	https://doi.org/10.1007/978-3-319-26236-9_7
State	Published - Oct 27 2017

Keywords

Hodgkin
Lymphoma
Response to therapy
Staging
[F]FDG
[F]FDG-PET/CT
non-Hodgkin

Access to Document

10.1007/978-3-319-26236-9_7

Cite this

@inbook{c9c4e1f5703c4f1395632839c380b4da,

title = "Diagnostic applications of nuclear medicine: Lymphomas",

abstract = "Hodgkin and non-Hodgkin lymphomas are lymphoid neoplasms arising from B cells, T cells, or NK (natural killer) cells. [18F]FDG PET/CT is more accurate for the primary staging of lymphoma, particularly because it can detect disease in normal-sized lymph nodes, liver, spleen, and bone marrow. A major advantage of [18F]FDG PET in determining the outcome of therapy is distinguishing active lymphoma from fibrosis/ necrosis in residual masses. Posttherapy [18F] FDG PET provides important prognostic information and has been incorporated into the currently used criteria for evaluating response to therapy in lymphoma (Lugano/Lyric Classifications). Interim [18F]FDG PET/CT also provides prognostic information and is being evaluated for {"}risk-adapted therapy{"} in setting of clinical trials.",

keywords = "Hodgkin, Lymphoma, Response to therapy, Staging, [F]FDG, [F]FDG-PET/CT, non-Hodgkin",

author = "Jacene, {Heather A.} and Tirumani, {Sree Harsha} and Wahl, {Richard L.}",

year = "2017",

month = oct,

day = "27",

doi = "10.1007/978-3-319-26236-9_7",

language = "English",

isbn = "9783319262345",

pages = "353--393",

booktitle = "Nuclear Oncology",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Diagnostic applications of nuclear medicine

T2 - Lymphomas

AU - Jacene, Heather A.

AU - Tirumani, Sree Harsha

AU - Wahl, Richard L.

PY - 2017/10/27

Y1 - 2017/10/27

N2 - Hodgkin and non-Hodgkin lymphomas are lymphoid neoplasms arising from B cells, T cells, or NK (natural killer) cells. [18F]FDG PET/CT is more accurate for the primary staging of lymphoma, particularly because it can detect disease in normal-sized lymph nodes, liver, spleen, and bone marrow. A major advantage of [18F]FDG PET in determining the outcome of therapy is distinguishing active lymphoma from fibrosis/ necrosis in residual masses. Posttherapy [18F] FDG PET provides important prognostic information and has been incorporated into the currently used criteria for evaluating response to therapy in lymphoma (Lugano/Lyric Classifications). Interim [18F]FDG PET/CT also provides prognostic information and is being evaluated for "risk-adapted therapy" in setting of clinical trials.

AB - Hodgkin and non-Hodgkin lymphomas are lymphoid neoplasms arising from B cells, T cells, or NK (natural killer) cells. [18F]FDG PET/CT is more accurate for the primary staging of lymphoma, particularly because it can detect disease in normal-sized lymph nodes, liver, spleen, and bone marrow. A major advantage of [18F]FDG PET in determining the outcome of therapy is distinguishing active lymphoma from fibrosis/ necrosis in residual masses. Posttherapy [18F] FDG PET provides important prognostic information and has been incorporated into the currently used criteria for evaluating response to therapy in lymphoma (Lugano/Lyric Classifications). Interim [18F]FDG PET/CT also provides prognostic information and is being evaluated for "risk-adapted therapy" in setting of clinical trials.

KW - Hodgkin

KW - Lymphoma

KW - Response to therapy

KW - Staging

KW - [F]FDG

KW - [F]FDG-PET/CT

KW - non-Hodgkin

UR - http://www.scopus.com/inward/record.url?scp=85055369127&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-26236-9_7

DO - 10.1007/978-3-319-26236-9_7

M3 - Chapter

AN - SCOPUS:85055369127

SN - 9783319262345

SP - 353

EP - 393

BT - Nuclear Oncology

PB - Springer International Publishing

ER -

Diagnostic applications of nuclear medicine: Lymphomas

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this